Findings from Hao Liu et al. [60] further revealed the pivotal role of the DNMT1/FOXO3a/FOXM1/SOX2 signaling cascade in regulating breast cancer stem cell (BCSC) properties, providing a rationale for developing therapeutics targeting this pathway to suppress BCSC-driven drug resistance. This evidence concerns the gene FOXM1 and breast carcinoma.